-
公开(公告)号：US20110293701A1
公开(公告)日：2011-12-01
申请号：US13116488
申请日：2011-05-26
IPC分类号： A61K9/127 , A61K39/116 , A61K39/00 , A61K38/21 , A61P31/00 , A61P35/00 , A61P25/30 , A61K39/295 , A61K9/14
CPC分类号： A61K45/06 , A61K9/5153 , A61K31/4745 , A61K31/7115 , A61K33/06 , A61K39/0005 , A61K39/0013 , A61K39/35 , A61K39/385 , A61K39/39 , A61K47/02 , A61K47/22 , A61K47/24 , A61K47/58 , A61K47/593 , A61K47/60 , A61K47/646 , A61K47/68 , A61K47/6921 , A61K47/6929 , A61K47/6931 , A61K2039/54 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/555 , A61K2039/55511 , A61K2039/55522 , A61K2039/55555 , A61K2039/55561 , A61K2039/6093 , A61K2039/70 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/401 , Y02A50/403 , Y02A50/466 , Y02A50/469 , Y02A50/478 , Y02A50/48 , Y02A50/484 , A61K2300/00
摘要： The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.
摘要翻译： 本发明至少部分涉及包含包含不同组抗原的合成纳米载体群以及相关方法的组合物。
-
公开(公告)号：US20110293700A1
公开(公告)日：2011-12-01
申请号：US13116453
申请日：2011-05-26
IPC分类号： A61K9/127 , A61K47/30 , A61K47/42 , A61K39/385 , A61P29/00 , A61K9/14 , A61P35/00 , A61P31/00 , A61P17/00 , A61P11/06 , A61P11/00 , A61K39/00 , A61P37/00
CPC分类号： A61K45/06 , A61K9/5153 , A61K31/4745 , A61K31/7115 , A61K33/06 , A61K39/0005 , A61K39/0013 , A61K39/35 , A61K39/385 , A61K39/39 , A61K47/02 , A61K47/22 , A61K47/24 , A61K47/58 , A61K47/593 , A61K47/60 , A61K47/646 , A61K47/68 , A61K47/6921 , A61K47/6929 , A61K47/6931 , A61K2039/54 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/555 , A61K2039/55511 , A61K2039/55522 , A61K2039/55555 , A61K2039/55561 , A61K2039/6093 , A61K2039/70 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/401 , Y02A50/403 , Y02A50/466 , Y02A50/469 , Y02A50/478 , Y02A50/48 , Y02A50/484 , A61K2300/00
摘要： Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.
摘要翻译： 公开了具有单独的佐剂组合物的合成纳米载体组合物以及相关方法。
-
公开(公告)号：US20110293723A1
公开(公告)日：2011-12-01
申请号：US13116556
申请日：2011-05-26
IPC分类号： A61K9/14 , A61K39/385 , A61K39/12 , A61K39/10 , A61K39/145 , A61K39/29 , A61K39/25 , A61K39/165 , A61K39/20 , A61K39/09 , A61K39/13 , A61K39/205 , A61K39/15 , A61K39/285 , A61K39/235 , A61K39/125 , A61K39/155 , A61K39/106 , A61K39/118 , A61K39/08 , A61K39/05 , A61K39/108 , A61K39/04 , A61K39/095 , A61K39/104 , A61K39/112 , A61K39/085 , A61P35/00 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/20 , A61P31/22 , A61K38/21 , A61K39/00 , B82Y5/00
CPC分类号： A61K45/06 , A61K9/5153 , A61K31/4745 , A61K31/7115 , A61K33/06 , A61K39/0005 , A61K39/0013 , A61K39/35 , A61K39/385 , A61K39/39 , A61K47/02 , A61K47/22 , A61K47/24 , A61K47/58 , A61K47/593 , A61K47/60 , A61K47/646 , A61K47/68 , A61K47/6921 , A61K47/6929 , A61K47/6931 , A61K2039/54 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/555 , A61K2039/55511 , A61K2039/55522 , A61K2039/55555 , A61K2039/55561 , A61K2039/6093 , A61K2039/70 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/401 , Y02A50/403 , Y02A50/466 , Y02A50/469 , Y02A50/478 , Y02A50/48 , Y02A50/484 , A61K2300/00
摘要： Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.
摘要翻译： 公开了剂型和相关方法，其包括具有一个或多个与其偶联的第一抗原的第一批合成纳米载体，一种或多种不与合成纳米载体偶联的第二抗原和药学上可接受的赋形剂。
-
公开(公告)号：US20110223201A1
公开(公告)日：2011-09-15
申请号：US12764569
申请日：2010-04-21
CPC分类号： B82Y5/00 , A61K47/593 , A61K47/60 , A61K47/6935 , A61K47/6937
摘要： Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable.
摘要翻译： 公开了合成纳米载体组合物和相关方法，用于治疗产生Th1偏向免疫应答的疾病。
-
公开(公告)号：US20170349433A1
公开(公告)日：2017-12-07
申请号：US15629973
申请日：2017-06-22
CPC分类号： B82Y5/00 , A61K47/593 , A61K47/60 , A61K47/6935 , A61K47/6937
摘要： Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a Th1-biased immune response is desirable.
-
公开(公告)号：US07776344B2
公开(公告)日：2010-08-17
申请号：US11179008
申请日：2005-07-08
CPC分类号： C12N15/117 , A61K38/21 , A61K2039/5154 , A61K2039/5158 , A61K2039/55561 , C12N5/0639 , C12N2501/056 , C12N2501/22 , C12N2501/23 , A61K2300/00
摘要： Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
摘要翻译： 提供了用于延长IFN-α在治疗各种病毒和增殖性疾病中的临床效用的方法和组合物。 在其它方面，本发明提供了增加IFN-α治疗功效并降低IFN-α治疗相关副作用的方法。 此外，提供了用于在体外支持生存和激活天然干扰素产生细胞（IPC）的方法，而没有外源IL-3或GM-CSF的方法。 本发明基于某些CpG和非CpG ISNA促进IPC的存活和刺激的发现。
-
7.发明申请公开(公告)号：US20110033421A1
公开(公告)日：2011-02-10
申请号：US12835000
申请日：2010-07-13
IPC分类号： A61K38/21 , A61K35/14 , A61P35/00 , A61P31/14 , A61P31/20 , A61P31/22 , A61P31/18 , C12N5/0784 , C07H21/04
CPC分类号： C12N15/117 , A61K38/21 , A61K2039/5154 , A61K2039/5158 , A61K2039/55561 , C12N5/0639 , C12N2501/056 , C12N2501/22 , C12N2501/23 , A61K2300/00
摘要： Methods and compositions are provided for extending the clinical utility of IFN-α in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-α treatment and reduce IFN-α treatment-related side effects. In addition, methods are provided for supporting the survival and for activating natural interferon producing cells (IPCs) in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.
摘要翻译： 提供了用于延长IFN-α在治疗各种病毒和增殖性疾病中的临床效用的方法和组合物。 在其它方面，本发明提供了增加IFN-α治疗功效并降低IFN-α治疗相关副作用的方法。 此外，提供了用于在体外支持生存和激活天然干扰素产生细胞（IPC）的方法，而没有外源IL-3或GM-CSF的方法。 本发明基于某些CpG和非CpG ISNA促进IPC的存活和刺激的发现。
-
公开(公告)号：US5167824A
公开(公告)日：1992-12-01
申请号：US479935
申请日：1990-02-14
申请人： Charles Cohen , Robert A. Dishman , James S. Huston , Robert L. Bratzler , David R. Dodds , Charles M. Zepp
发明人： Charles Cohen , Robert A. Dishman , James S. Huston , Robert L. Bratzler , David R. Dodds , Charles M. Zepp
CPC分类号： B01D61/246 , B01D11/0415 , B01D61/38 , C07B57/00 , C07K1/22 , G01N33/537
摘要： Disclosed are processes and apparatus for separating a desired solute, such as an optically active isomer, from a complex mixture using carrier facilitated transport in an immobilized liquid membrane or carrier facilitated solvent extraction. The carrier is a binding protein selected and/or engineered to immunochemically reversibly bind to the solute and to have a significant solubility in the extracting solvent or immobilized liquid membrane.
摘要翻译： 公开了使用载体促进转运在固定液膜或载体中促进溶剂萃取的方法和装置，用于从复杂混合物中分离出期望的溶质如旋光异构体。 载体是选择和/或工程化以免疫化学可逆地结合溶质并且在萃取溶剂或固定化液膜中具有显着溶解度的结合蛋白。
-
9.发明申请公开(公告)号：US20090155212A1
公开(公告)日：2009-06-18
申请号：US12287382
申请日：2008-10-07
IPC分类号： A61K38/21 , A61K31/7088 , A61K39/00 , A61P35/00
CPC分类号： A61K45/06 , A61K31/00 , A61K38/212 , A61K39/0011 , A61K2039/55561 , A61K2300/00
摘要： The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.
-
公开(公告)号：US20100189772A1
公开(公告)日：2010-07-29
申请号：US12443224
申请日：2007-09-27
申请人： Jorg Vollmer , Marion Jurk , Eugen Uhlmann , Harald Debelak , Robert L. Bratzler , Alain Vicari
发明人： Jorg Vollmer , Marion Jurk , Eugen Uhlmann , Harald Debelak , Robert L. Bratzler , Alain Vicari
CPC分类号： A61K31/7088 , A61K45/06 , C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/336 , C12N2310/351 , C12N2320/31 , A61K2300/00
摘要： The invention relates to methods and products for the treatment of viral infection using a combination of anti-viral agents and TLR ligands. The invention also relates to screening assays, associated products, kits, and in vitro methods.
摘要翻译： 本发明涉及使用抗病毒剂和TLR配体的组合治疗病毒感染的方法和产品。 本发明还涉及筛选测定，相关产品，试剂盒和体外方法。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.03 秒)
